Teva Pharmaceutical Industries Ltd (TEVA.N)
40.41USD
12:35pm EDT
$0.18 (+0.45%)
$40.23
$40.11
$40.48
$40.05
198,974
559,619
$42.82
$36.64
TEVA.N
About
Overall
| Beta: | 0.39 |
| Market Cap (Mil.): | $37,450.74 |
| Shares Outstanding (Mil.): | 943.82 |
| Dividend: | 0.32 |
| Yield (%): | 2.82 |
Financials
| TEVA.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 17.96 | 35.66 | 35.83 |
| EPS (TTM): | 2.24 | -- | -- |
| ROI: | 5.29 | 19.36 | 18.72 |
| ROE: | 8.73 | 20.07 | 19.54 |
UPDATE 1-Sanofi fined in Plavix generics dispute
* Sanofi may appeal decision, shares down 0.6 percent (Adds details, Sanofi comments, shares)
REFILE-Israel finance minister seeks to curb corporate tax benefits
JERUSALEM, May 10 - Israel's finance minister said on Friday he intends to rein in the tax benefits that major companies are granted in Israel.
Teva to market Alexza agitation treatment in the U.S
TEL AVIV - Teva Pharmaceutical Industries and Alexza Pharmaceuticals reached an exclusive U.S. license and supply agreement for Adasuve inhalation powder for the treatment of agitation associated with schizophrenia or bipolar I disorder in adults.
Teva to market Alexza agitation treatment in the U.S.
TEL AVIV, May 8 - Teva Pharmaceutical Industries and Alexza Pharmaceuticals reached an exclusive U.S. license and supply agreement for Adasuve inhalation powder for the treatment of agitation associated with schizophrenia or bipolar I disorder in adults.
Teva better suited than most for China market: CEO
NEW YORK - Teva Pharmaceutical Industries Ltd has yet to make any serious inroads into China, but its chief executive believes the company is better suited than its rival drugmakers to serve the world's fastest growing health care market.
Teva Pharmaceutical banks on thrice-weekly Copaxone
TEL AVIV - Teva Pharmaceutical Industries is banking on approval in early 2014 for a new thrice-weekly version of its multiple sclerosis treatment Copaxone to bolster sales ahead of a likely onslaught from copies of its best-selling drug.
UPDATE 1-Teva Pharmaceutical banks on thrice-weekly Copaxone
TEL AVIV, May 2 - Teva Pharmaceutical Industries is banking on approval in early 2014 for a new thrice-weekly version of its multiple sclerosis treatment Copaxone to bolster sales ahead of a likely onslaught from copies of its best-selling drug.
Teva CEO sees Q1 2014 FDA action on 3-times-a-week Copaxone
JERUSALEM, May 2 - Teva Pharmaceutical Industries , the world's largest generic drugmaker, expects U.S. regulators to act on its more convenient three-times-a-week dosing regimen of multiple sclerosis drug Copaxone in early 2014.
Drugs from Amgen, others assessed by FDA as radiation treatments
- Drugs from Amgen Inc, Teva Pharmaceutical Industries and Sanofi that boost white blood cells are being evaluated by U.S. regulators as treatments for radiation exposure caused by a nuclear attack or accident.
Drugs from Amgen, others assessed by FDA as radiation treatments
May 1 - Drugs from Amgen Inc, Teva Pharmaceutical Industries and Sanofi that boost white blood cells are being evaluated by U.S. regulators as treatments for radiation exposure caused by a nuclear attack or accident.
Competitors
| Price | Change | |
|---|---|---|
| Novartis AG (NOVN.VX) | CHF71.75 | -0.45 |
| Momenta Pharmaceuticals, Inc. (MNTA.OQ) | $12.76 | -0.27 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Jefferson Research
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
